These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 32187230

  • 1. Targeting glycosphingolipid metabolism as a potential therapeutic approach for treating disease in female MRL/lpr lupus mice.
    Nowling TK, Rodgers J, Thiyagarajan T, Wolf B, Bruner E, Sundararaj K, Molano I, Gilkeson G.
    PLoS One; 2020; 15(3):e0230499. PubMed ID: 32187230
    [Abstract] [Full Text] [Related]

  • 2. Renal glycosphingolipid metabolism is dysfunctional in lupus nephritis.
    Nowling TK, Mather AR, Thiyagarajan T, Hernández-Corbacho MJ, Powers TW, Jones EE, Snider AJ, Oates JC, Drake RR, Siskind LJ.
    J Am Soc Nephrol; 2015 Jun; 26(6):1402-13. PubMed ID: 25270066
    [Abstract] [Full Text] [Related]

  • 3. FLI1 Levels Impact CXCR3 Expression and Renal Infiltration of T Cells and Renal Glycosphingolipid Metabolism in the MRL/lpr Lupus Mouse Strain.
    Sundararaj KP, Thiyagarajan T, Molano I, Basher F, Powers TW, Drake RR, Nowling TK.
    J Immunol; 2015 Dec 15; 195(12):5551-60. PubMed ID: 26538397
    [Abstract] [Full Text] [Related]

  • 4. Neuraminidase activity mediates IL-6 production by activated lupus-prone mesangial cells.
    Sundararaj K, Rodgers JI, Marimuthu S, Siskind LJ, Bruner E, Nowling TK.
    Am J Physiol Renal Physiol; 2018 Apr 01; 314(4):F630-F642. PubMed ID: 29357434
    [Abstract] [Full Text] [Related]

  • 5. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
    Shi Y, Yao W, Sun L, Li G, Liu H, Ding P, Hu W, Xu H.
    BMC Nephrol; 2019 Nov 21; 20(1):424. PubMed ID: 31752725
    [Abstract] [Full Text] [Related]

  • 6. Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice.
    Kadiombo AT, Maeshima A, Kayakabe K, Ikeuchi H, Sakairi T, Kaneko Y, Hiromura K, Nojima Y.
    Am J Physiol Renal Physiol; 2017 Feb 01; 312(2):F297-F304. PubMed ID: 27881396
    [Abstract] [Full Text] [Related]

  • 7. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis.
    Oates JC, Halushka PV, Hutchison FN, Ruiz P, Gilkeson GS.
    Am J Med Sci; 2011 Feb 01; 341(2):101-5. PubMed ID: 20924284
    [Abstract] [Full Text] [Related]

  • 8. The role of neuraminidase 1 (NEU1) in cytokine release by primary mouse mesangial cells and disease outcomes in murine lupus nephritis.
    Rodgers J, Sundararaj K, Bruner E, Wolf B, Nowling TK.
    Autoimmunity; 2021 May 01; 54(3):163-175. PubMed ID: 33749450
    [Abstract] [Full Text] [Related]

  • 9. Proteomics-Based Identification of Potential Therapeutic Targets of Artesunate in a Lupus Nephritis MRL/lpr Mouse Model.
    Wen Q, Wang C, Chen D, Luo N, Fan J, Zhou Y, Yu X, Chen W.
    J Proteome Res; 2024 Apr 05; 23(4):1150-1162. PubMed ID: 38394376
    [Abstract] [Full Text] [Related]

  • 10. The role of neuraminidase in TLR4-MAPK signalling and the release of cytokines by lupus serum-stimulated mesangial cells.
    Sundararaj K, Rodgers J, Angel P, Wolf B, Nowling TK.
    Immunology; 2021 Apr 05; 162(4):418-433. PubMed ID: 33314123
    [Abstract] [Full Text] [Related]

  • 11. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
    Lui SL, Tsang R, Wong D, Chan KW, Chan TM, Fung PC, Lai KN.
    Lupus; 2002 Apr 05; 11(7):411-8. PubMed ID: 12195781
    [Abstract] [Full Text] [Related]

  • 12. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan 05; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 13. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
    Mannoor K, Matejuk A, Xu Y, Beardall M, Chen C.
    J Immunol; 2012 Apr 15; 188(8):3628-38. PubMed ID: 22407922
    [Abstract] [Full Text] [Related]

  • 14. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
    Pérez de Lema G, Lucio-Cazaña FJ, Molina A, Luckow B, Schmid H, de Wit C, Moreno-Manzano V, Banas B, Mampaso F, Schlöndorff D.
    Kidney Int; 2004 Sep 15; 66(3):1018-28. PubMed ID: 15327395
    [Abstract] [Full Text] [Related]

  • 15. Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice.
    Iwata Y, Boström EA, Menke J, Rabacal WA, Morel L, Wada T, Kelley VR.
    J Immunol; 2012 May 01; 188(9):4568-80. PubMed ID: 22467656
    [Abstract] [Full Text] [Related]

  • 16. Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice.
    Menke J, Bork T, Kutska B, Byrne KT, Blanfeld M, Relle M, Kelley VR, Schwarting A.
    Kidney Int; 2011 Feb 01; 79(4):452-63. PubMed ID: 20980973
    [Abstract] [Full Text] [Related]

  • 17. Procyanidin B2 prevents lupus nephritis development in mice by inhibiting NLRP3 inflammasome activation.
    He J, Sun M, Tian S.
    Innate Immun; 2018 Jul 01; 24(5):307-315. PubMed ID: 29874961
    [Abstract] [Full Text] [Related]

  • 18. Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(lpr) mice with lupus nephritis.
    Wüthrich RP, Fan X, Ritthaler T, Sibalic V, Yu DJ, Loffing J, Kaissling B.
    Autoimmunity; 1998 Jul 01; 28(3):139-50. PubMed ID: 9867126
    [Abstract] [Full Text] [Related]

  • 19. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
    Yao L, Chen HP, Ma Q.
    Immunol Lett; 2014 Sep 01; 161(1):76-80. PubMed ID: 24837470
    [Abstract] [Full Text] [Related]

  • 20. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C.
    Clin Immunol; 2018 Dec 01; 197():205-218. PubMed ID: 30339790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.